Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study
Patrick G A Oomen,Ferdinand W N M Wit,Kees Brinkman,Saskia M E Vrouenraets,Tania Mudrikova,Berend J van Welzen,Marc van der Valk,ATHENA National Observational Cohort Study,M A van Agtmael,M Bomers,S E Geerlings,A Goorhuis,V C Harris,J W Hovius,B Lemkes,F J B Nellen,E J G Peters,T van der Poll,J M Prins,K C E Sigaloff,V Spoorenberg,M van Vugt,W J Wiersinga,C Bruins,J van Eden,I J Hylkema-van den Bout,L M Laan,F J J Pijnappel,S Y Smalhout,M E Spelbrink,A M Weijsenfeld,N K T Back,M T E Cornelissen,R van Houdt,M Jonges,S Jurriaans,C J Schinkel,M R A Welkers,K C Wolthers,M van den Berge,A Stegeman,S Baas,L Hage de Looff,A van Arkel,J Stohr,B Wintermans,M J H Pronk,H S M Ammerlaan,C de Bree,E S de Munnik,S Phaf,B Deiman,A R Jansz,V Scharnhorst,J Tjhie,M C A Wegdam,J Nellen,A van Eeden,E Hoornenborg,S de Stoppelaar,W Alers,L J M Elsenburg,H Nobel,M E E van Kasteren,M A H Berrevoets,A E Brouwer,B A F M de Kruijf-van de Wiel,A Adams,M Pawels-van Rijkevoorsel,J L Murck,C Rokx,A A Anas,H I Bax,E C M van Gorp,M de Mendonça Melo,E van Nood,J L Nouwen,B J A Rijnders,C A M Schurink,L Slobbe,T E M S de Vries-Sluijs,N Bassant,J E A van Beek,M Vriesde,L M van Zonneveld,J de Groot,J J A van Kampen,M P G Koopmans,J C Rahamat-Langendoen,J Branger,R A Douma,A S Cents-Bosma,M A Mulder,E F Schippers,C van Nieuwkoop,J Geilings,E van de Ven,G van der Hut,N D van Burgel,E M S Leyten,L B S Gelinck,F Mollema,M Langbein,G S Wildenbeest,T Nguyen,P H P Groeneveld,J W Bouwhuis,A J J Lammers,A G W van Hulzen,S Kraan,M S M Kruiper,S B Debast,G H J Wagenvoort,A H E Roukens,M G J de Boer,H Jolink,M M C Lambregts,H Scheper,N van Holten,D van der Sluis,E C J Claas,E Wessels,J G den Hollander,R El Moussaoui,K Pogany,C J Brouwer,D Heida-Peters,E Mulder,J V Smit,D Struik-Kalkman,T van Niekerk,O Pontesilli,C van Tienen,S H Lowe,A M L Oude Lashof,D Posthouwer,A Stoop,M E van Wolfswinkel,R P Ackens,M Elasri,K Houben-Pintaric,J Schippers,T R A Havenith,M van Loo,M G A van Vonderen,L M Kampschreur,C Timmer,M C van Broekhuizen,S Faber,A Al Moujahid,G J Kootstra,C E Delsing,M van der Burg-van de Plas,L Scheiberlich,W Kortmann,G van Twillert,R Renckens,J Wagenaar,D Ruiter-Pronk,B Stander,J W T Cohen Stuart,M Hoogewerf,W Rozemeijer,J C Sinnige,K Brinkman,G E L van den Berk,K D Lettinga,M de Regt,W E M Schouten,J E Stalenhoef,H Blaauw,G F Geerders,M J Kleene,M Knapen,M Kok,I B van der Meché,A J M Toonen,S Wijnands,E Wttewaal,D Kwa,T J W van de Laar,R van Crevel,K van Aerde,A S M Dofferhoff,S S V Henriet,H J M Ter Hofstede,J Hoogerwerf,O Richel,M Albers,K J T Grintjes-Huisman,M de Haan,M Marneef,M McCall,J Rahamat-Langendoen,E Ruizendaal,D Burger,E H Gisolf,M Claassen,R J Hassing,G Ter Beest,P H M van Bentum,Y Neijland,M Valette,C M A Swanink,M Klein Velderman,S F L van Lelyveld,R Soetekouw,L M M van der Prijt,J van der Swaluw,J S Kalpoe,A Wagemakers,A Vahidnia,F N Lauw,D W M Verhagen,M van Wijk,W F W Bierman,M Bakker,R A van Bentum,M A van den Boomgaard,J Kleinnijenhuis,E Kloeze,A Middel,D F Postma,H M Schenk,Y Stienstra,M Wouthuyzen-Bakker,A Boonstra,M M M Maerman,D A de Weerd,K J van Eije,M Knoester,C C van Leer-Buter,H G M Niesters,R E Barth,A H W Bruns,P M Ellerbroek,M P M Hensgens,J J Oosterheert,E M Schadd,A Verbon,B M G Griffioen-van Santen,I de Kroon,R Schuurman,F M Verduyn Lunel,A M J Wensing,M van der Valk,S Zaheri,A C Boyd,D O Bezemer,V W Jongen,A I van Sighem,C Smit,F W M N Wit,M M J Hillebregt,T J Woudstra,T Rutkens,D Bergsma,N M Brétin,L E Koster,K J Lelivelt,L van de Sande,M J C Schoorl,K M Visser,S T van der Vliet,F Paling,M van den Akker,O M Akpomukai,R Alexander,Y M Bakker,L Bastos Sales,A El Berkaoui,M Bezemer-Goedhart,E A Djoechro,J M Grolleman,I El Hammoud,M R Khouw,C R E Lodewijk,E G A Lucas,S van Meerveld-Derks,H W Mulder,L Munjishvili,C M J Ree,R Regtop,A F van Rijk,Y M C Ruijs-Tiggelman,P P Schnörr,R van Veen,W H G van Vliet-Klein Gunnewiek,E C M Witte
DOI: https://doi.org/10.1016/S2352-3018(24)00150-4
Abstract:Background: Currently, real-world data on doravirine are scarce. In a national prospective cohort, we assessed the effectiveness and tolerability of switching to doravirine-based antiretroviral therapy (ART) in people with HIV. Methods: We did a nationwide, matched, prospective cohort study of people with HIV without previous virological failure and stable for at least 12 months on non-doravirine-containing triple or dual ART switching to doravirine before Sept 1, 2020 (exposed group). Participants in the exposed group were matched 1:2 to individuals continuing stable non-doravirine-containing ART, on age, sex, HIV acquisition category, time since ART initiation, calendar time, pre-ART CD4-count, pre-ART plasma viral load (PVL) and anchor drug class before switching. The primary outcome was protocol-defined virological failure (PDVF; PVL of ≥200 copies per mL) in the intention-to-treat (ITT) population at week 104, with participants modifying their regimen or becoming lost to follow-up considered as PDVF (non-inferiority margin +5%). In contrast, in the on-treatment population, those who modified their regimen or became lost to follow-up were censored from that moment onwards. Tolerability was a secondary outcome. Findings: In total, 590 participants in the exposed group and 1180 participants in the unexposed group (of whom 55·3% used integrase strand transfer inhibitor-based regimens) were included. In the ITT analysis, PDVF occurred in 135 (22·9%) exposed participants and in 295 (25·0%) unexposed participants (risk difference -2·12%, upper limit of the one-sided 95% CI +1·40%). In the on-treatment analysis, 10 (2·2%) of 455 non-censored exposed participants and 26 (2·9%) of 885 non-censored unexposed participants had PDVF (risk difference -0·70%, upper limit of the one-sided 95% CI +0·73%). All exposed participants with a PVL of 200 copies or more per mL resuppressed without regimen modification: no confirmed virological failure (two consecutive PVLs of ≥200 copies per mL) was observed. 104 (17·6%) exposed participants and 211 (17·9%) unexposed participants modified their regimen. 73 (12.4%) exposed participants discontinued doravirine due to adverse events: abnormal dreams (1·7%) and insomnia (1·5%) were most common. Interpretation: Switching to doravirine in well suppressed people with HIV without previous virological failure was non-inferior compared with continuing non-doravirine-containing regimens after 2 years in a real-world setting. Funding: None.